Detalles de la búsqueda
1.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
BMC Cancer
; 18(1): 965, 2018 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30305055
2.
Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
Hepatology
; 57(5): 1838-46, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23299860
3.
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Gynecol Oncol
; 132(2): 334-42, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24368280
4.
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Breast Cancer Res Treat
; 141(3): 397-408, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24091768
5.
Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.
Genes Chromosomes Cancer
; 50(2): 95-112, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21117066
6.
Periostin promotes ovarian cancer angiogenesis and metastasis.
Gynecol Oncol
; 119(2): 337-44, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20688362
7.
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Breast Cancer Res
; 11(5): R77, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19874578
8.
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
J Natl Cancer Inst
; 106(10)2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25269487
9.
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Mol Cancer Ther
; 12(6): 1002-15, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23729402
10.
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Anticancer Res
; 33(8): 2997-3004, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23898052
11.
Expression of Wnt3 activates Wnt/ß-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
Mol Cancer Res
; 10(12): 1597-606, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23071104
12.
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Mol Cancer Ther
; 11(9): 1978-87, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22761403
13.
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Clin Cancer Res
; 17(6): 1591-602, 2011 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21278246
14.
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
Mol Cancer Ther
; 9(6): 1489-502, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20501798
15.
RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.
Lung Cancer
; 70(3): 253-62, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20338664
16.
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Neoplasia
; 12(8): 637-49, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20689758
17.
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
Mol Cancer Ther
; 9(7): 1985-94, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20587667
18.
ERCC5 is a novel biomarker of ovarian cancer prognosis.
J Clin Oncol
; 26(18): 2952-8, 2008 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-18565881
19.
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Breast Cancer Res Treat
; 105(3): 319-26, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17268817
Resultados
1 -
19
de 19
1
Próxima >
>>